<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194985</url>
  </required_header>
  <id_info>
    <org_study_id>AT1001-042</org_study_id>
    <nct_id>NCT02194985</nct_id>
  </id_info>
  <brief_title>Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease</brief_title>
  <official_title>An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label extension study intended to provide continued treatment with migalastat
      HCl for subjects with Fabry disease who completed treatment of a previous migalastat HCl
      monotherapy study.

      The study will assess the long-term safety and effectiveness of migalastat HCl in subjects
      with Fabry disease who completed migalastat HCl treatment in a previous study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>non-serious AEs, serious AEs., possible suicidality related AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal due to AEs</measure>
    <time_frame>up to 5 years</time_frame>
    <description>including non-serious and serious AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs and body weight - change in baseline in vital signs and body weight</measure>
    <time_frame>up to 5 years</time_frame>
    <description>blood pressure and heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in laboratory parameters</measure>
    <time_frame>up to 5 years</time_frame>
    <description>hematology, chemistry, and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in electrocardiogram (ECG)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in echocardiography</measure>
    <time_frame>up to 5 years</time_frame>
    <description>echocardiography ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>based on the Modification of Diet in Renal Disease (MDRD) equation and CKD-EPI equation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of left ventricular mass (LVM) and left ventricular mass index (LVMi)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>as measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>as measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fractional shortening</measure>
    <time_frame>up to 5 years</time_frame>
    <description>as assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of LV internal dimension (LVIDd and LVIDs) and wall thickness</measure>
    <time_frame>up to 5 years</time_frame>
    <description>as assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of white blood cell (WBC) α-Gal A activity</measure>
    <time_frame>up to 5 years</time_frame>
    <description>enzyme responsible for breaking down GL-3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of subject reported Quality of Life</measure>
    <time_frame>up to 5 years</time_frame>
    <description>as assessed by the Short Form - 36 Survey (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of 24-hour urine protein</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lyso-Gb3</measure>
    <time_frame>up to 5 years</time_frame>
    <description>biomarker shown to be elevated in Fabry subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>migalastat HCl 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Migalastat HCl is a capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on days between migalastat HCl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>migalastat HCl 150 mg</intervention_name>
    <description>Capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on the days between migalastat HCl.</description>
    <arm_group_label>migalastat HCl 150 mg</arm_group_label>
    <other_name>AT1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject had completed treatment in a previous study of migalastat HCl

          -  Age 18 years or older

          -  Male and female participant agrees to use protocol identified acceptable contraception

          -  Subject is willing to provide written informed consent and authorization for use and
             disclosure of Personal Health Information (PHI)

        Exclusion Criteria:

          -  Subjects last available estimated glomerular filtration rate (eGFR) in the previous
             study was &lt;30 mL/min/1.73m2; unless there is measured GFR available within 3 months of
             Baseline Visit (Visit 1), which is &gt;30 mL/min/1.73m2

          -  Subject has undergone, or is scheduled to undergo kidney transplantation or is
             currently on dialysis

          -  Subject has a documented transient ischemic attack, stroke, unstable angina, or
             myocardial infarction within the 3 months before Visit 1

          -  Subject has clinically significant unstable cardiac disease in the opinion of the
             investigator (e.g., cardiac disease requiring active management, such as symptomatic
             arrhythmia, unstable angina, or NYHA class III or IV congestive heart failure)

          -  Subject has a history of allergy or sensitivity to AT1001 (including excipients) or
             other iminosugars (e.g., miglustat, miglitol)

          -  Subject requires treatment with Glyset® (miglitol) or Zavesca® (miglustat)

          -  Subjects with severe or unsuitable concomitant medical condition

          -  Subjects with clinically significant abnormal laboratory value(s) and clinically
             significant electrocardiogram (ECG) findings at baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, Clinical Research, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amicus Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infusion Associates N.E.</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O &amp; O Alpan, LLC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's and Children's Hospital</name>
      <address>
        <city>North Adelaide</city>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antwerpen Koningin Paola Kinderziekenhuis</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kasr El Ainy Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Raymond Poincare</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871, 27</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>951-8520, 15</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <zip>545-8586, 27</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jikei University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8471-13</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Puigvert</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gazi University Medical Faculty Gazi</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles Dent Metabolic Unit</name>
      <address>
        <city>London</city>
        <zip>WC1N3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2014</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Lysosomal storage disease</keyword>
  <keyword>migalastat HCl</keyword>
  <keyword>AT1001</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>1-Deoxynojirimycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

